Blog
RSS FeedPosted by Michael Wonder on 26 Aug 2025
Datroway approved in China for patients with previously treated metastatic HR positive, HER2 negative breast cancer
25 August 2025 - First approval in China for Daiichi Sankyo and AstraZeneca’s Datroway based on TROPIONBreast01 results showing 37% reduction ...
Posted by Michael Wonder on 25 Aug 2025
Moderna receives Health Canada approval for updated COVID-19 vaccine targeting SARS-CoV-2 variant LP.8.1
22 August 2025 - All 2025 pre-filled syringe doses to be made in Canada, marking a domestic production milestone. ...
Posted by Michael Wonder on 25 Aug 2025
Health Canada approves Roche’s Columvi (glofitamab) as the first bi-specific antibody in Canada for relapsed or refractory diffuse large B-cell lymphoma after initial therapy
21 August 2025 - Approval is based on Phase 3 STARGLO study where Columvi in combination with chemotherapy showed a ...
Posted by Michael Wonder on 25 Aug 2025
European Commission approves tablet formulation of BeOne Medicines’ Brukinsa for all approved indications
21 August 2025 - Tablets will advance treatment simplicity and convenience to meet patient needs across Europe. ...
Posted by Michael Wonder on 25 Aug 2025
Bewildering PBAC decision a missed opportunity to ensure Australian cancer patients not left behind
23 August 2025 - MSD Australia & New Zealand is astonished that after eight years of dialogue and consideration, the ...
Posted by Michael Wonder on 25 Aug 2025
Recommendations made the PBAC – July 2025
22 August 2025 - The recommendations from the July 2025 PBAC meeting are now available. ...
Posted by Michael Wonder on 25 Aug 2025
Committee rejects application for medication Keytruda to be subsidised for Aussies with cancer
23 August 2025 - Australians with rare cancers like Natalie Willacy have just been handed a devastating hit, which could leave ...
Posted by Michael Wonder on 25 Aug 2025
Injectable form of Ocrevus for relapsing remitting multiple sclerosis recommended for PBS listing
22 August 2025 - This new form of ocrelizumab is given as an injection under the skin (subcutaneously), takes a much ...
Posted by Michael Wonder on 24 Aug 2025
New Alzheimer’s drug rejected for PBS listing, leaving patients to pay up to $80k a year
23 August 2025 - New Alzheimer’s drug rejected for PBS listing, leaving patients to pay up to $80k/year. ...
Posted by Michael Wonder on 22 Aug 2025
Health Canada grants marketing authorisation for an additional indication of Bayer's Nubeqa (darolutamide) for the treatment of metastatic castration-sensitive prostate cancer
21 August 2025 - Bayer is pleased to announce that Health Canada has granted marketing authorisation for its oral androgen receptor ...
Posted by Michael Wonder on 21 Aug 2025
Dawnzera (donidalorsen) approved in the US as first and only RNA targeted prophylactic treatment for hereditary angioedema
21 August 2025 - Offers longest dosing option for hereditary angioedema, with dosing every 4 or 8 weeks. ...
Posted by Michael Wonder on 20 Aug 2025
First of its kind Ozempic listing for kidney disease
19 August 2025 - Regulators have approved Ozempic’s use for kidney disease treatment, opening the door to new combination therapies. ...
Posted by Michael Wonder on 20 Aug 2025
Madrigal receives European Commission approval for Rezdiffra (resmetirom) for the treatment of MASH with moderate to advanced liver fibrosis
19 August 2025 - Conditional marketing authorisation is based on positive results from the pivotal Phase 3 MAESTRO-NASH trial demonstrating Rezdiffra ...
Posted by Michael Wonder on 20 Aug 2025
Health Canada approves dual immunotherapy Opdivo plus Yervoy for colorectal and liver cancers
19 August 2025 - Bristol Myers Squibb Canada today announced that Health Canada has approved Opdivo (nivolumab) in combination with ...
Posted by Michael Wonder on 20 Aug 2025
Health Canada approves Ozempic to reduce the risk of sustained eGFR decline, end stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease
19 August 2025 - Novo Nordisk announced today that Ozempic (semaglutide injection) is now approved as the first and only ...